Photocure Total Assets
Photocure total assets. Based on the latest financial reports, Photocure (PHO) holds total assets worth Nkr901.41 Million NOK (≈ $94.85 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PHO cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Photocure (2000–2025)
Total assets of Photocure from 2000 to 2025. This chart illustrates how Photocure's total assets have evolved over time, based on quarterly financial data. See Photocure stock quote for real-time trading data and today's change.
Photocure - Asset Composition Analysis
Photocure Total Assets Breakdown (December 2025)
Photocure total assets breakdown as of December 2025. Photocure's total assets of Nkr901.41 Million consist of 54.6% current assets and 45.4% non-current assets. Explore PHO current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr238.89 Million | 33.8% |
| Accounts Receivable | Nkr74.92 Million | 10.6% |
| Inventory | Nkr44.37 Million | 6.3% |
| Property, Plant & Equipment | Nkr42.20 Million | 6.0% |
| Intangible Assets | Nkr79.19 Million | 11.2% |
| Goodwill | Nkr144.00 Million | 20.4% |
Asset Composition Trend (2000–2025)
This chart illustrates how Photocure's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Photocure's current assets represent 54.6% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 33.8% of total assets in 2025, up from 7.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is cash and equivalents at 33.8% of total assets.
Photocure Competitors by Total Assets
Key competitors of Photocure based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Photocure - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.65 | 4.78 | 5.12 |
| Quick Ratio | 3.11 | 4.29 | 4.77 |
| Cash Ratio | 0.00 | 3.08 | 4.08 |
| Working Capital | Nkr268.44 Million | Nkr293.34 Million | Nkr333.27 Million |
Photocure - Advanced Valuation Insights
This section examines the relationship between Photocure's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -4.3% |
| Total Assets | Nkr707.06 Million |
| Market Capitalization | $131.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Photocure's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Photocure's assets decreased by 4.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Photocure (2000–2025)
The table below shows the annual total assets of Photocure from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr707.06 Million ≈ $74.40 Million |
-4.33% |
| 2024-12-31 | Nkr739.09 Million ≈ $77.77 Million |
+3.81% |
| 2023-12-31 | Nkr711.97 Million ≈ $74.92 Million |
-0.98% |
| 2022-12-31 | Nkr719.03 Million ≈ $75.66 Million |
-8.94% |
| 2021-12-31 | Nkr789.65 Million ≈ $83.09 Million |
+1.75% |
| 2020-12-31 | Nkr776.05 Million ≈ $81.66 Million |
+201.55% |
| 2019-12-31 | Nkr257.35 Million ≈ $27.08 Million |
+11.31% |
| 2018-12-31 | Nkr231.20 Million ≈ $24.33 Million |
-12.13% |
| 2017-12-31 | Nkr263.10 Million ≈ $27.69 Million |
-7.96% |
| 2016-12-31 | Nkr285.85 Million ≈ $30.08 Million |
+15.24% |
| 2015-12-31 | Nkr248.06 Million ≈ $26.10 Million |
-8.32% |
| 2014-12-31 | Nkr270.58 Million ≈ $28.47 Million |
-10.32% |
| 2013-12-31 | Nkr301.73 Million ≈ $31.75 Million |
-30.31% |
| 2012-12-31 | Nkr432.98 Million ≈ $45.56 Million |
-14.97% |
| 2011-12-31 | Nkr509.18 Million ≈ $53.58 Million |
-0.91% |
| 2010-12-31 | Nkr513.84 Million ≈ $54.07 Million |
+12.47% |
| 2009-12-31 | Nkr456.86 Million ≈ $48.08 Million |
+92.08% |
| 2008-12-31 | Nkr237.85 Million ≈ $25.03 Million |
-21.08% |
| 2007-12-31 | Nkr301.39 Million ≈ $31.72 Million |
-19.72% |
| 2006-12-31 | Nkr375.42 Million ≈ $39.51 Million |
+255.16% |
| 2005-12-31 | Nkr105.70 Million ≈ $11.12 Million |
-39.15% |
| 2004-12-31 | Nkr173.71 Million ≈ $18.28 Million |
-25.57% |
| 2003-12-31 | Nkr233.40 Million ≈ $24.56 Million |
-21.94% |
| 2002-12-31 | Nkr299.01 Million ≈ $31.46 Million |
-6.43% |
| 2001-12-31 | Nkr319.57 Million ≈ $33.63 Million |
-21.06% |
| 2000-12-31 | Nkr404.85 Million ≈ $42.60 Million |
-- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination pro… Read more